To assess safety of fixed dose combination of dapagliflozin and saxagliptin in Type 2 Diabetes Mellitus patients

Study identifier:D1683C00013

ClinicalTrials.gov identifier:NCT04445714

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A prospective, multicenter, phase -IV study to assess the safety of fixed dose combination of dapagliflozin and saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) patients

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 4

Healthy volunteers

No

Study drug

dapagliflozin and saxagliptin

Sex

All

Actual Enrollment

196

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 07 Apr 2021
Primary Completion Date: 14 Mar 2023
Study Completion Date: 14 Mar 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria